Fig 1: The expression of PD-1 by patient-derived or murine BTICs in culture.(A) Following surgery of patients with GBM, BTICs were generated from resected specimens by culturing cells in a serum-free medium supplemented with EGF and FGF. RT-qPCR analysis of PD-1 transcripts in (B) human (PDCD1) or (C) mouse (Pdcd1) BTIC lines compared with neural stem cells (NSCs). Fold changes were calculated relative to PD-1 expression in neural stem cells and normalized to GAPDH expression. Immunofluorescence of PD-1 staining on (D) human and (E) mouse BTIC lines in culture. Active T cells or splenocytes were used as controls. Nuclei were counterstained with DAPI. Representative flow cytometry plots of PD-1 expression on (F) human and (G) mouse BTIC lines, with quantitation and comparison to human or mouse neural stem cells shown in (H) and (I), respectively. Human or mouse BTICs (OE) PDCD1 or Pdcd1 and active T cells or splenocytes were used as controls. T cells or splenocytes were activated with anti-CD3/CD28 antibodies. Recently initiated patient-derived BTICs from two resections (BT2313 and BT2314), with less than two passages in culture, were also tested. Human and mouse cells were stained with antibodies conjugated with allophycocyanin (APC) or phycoerythrin (PE) fluorochromes, respectively. Data are representative of two to three independent experiments. Means were compared to neural stem cells with unpaired (two-tailed) t test, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Data are represented as means ± SEM. See also figs. S2 and S3 and table S2. Ab, antibody.
Fig 2: The expression of PD-1 on BTICs in resected clinical GBM specimens in situ.Representative images of immunofluorescence staining and corresponding 3D reconstruction of images of (A and B) CD45 and PD-1, (C and D) PD-1 and BTIC marker SOX2, and (E and F) PD-1 and BTIC marker nestin in sections of human GBM specimens resected from three patients (1085, 110907, and 101029). Representative immunofluorescence images of human normal brains stained for (G) PD-1 and SOX2 or (H) PD-1 and nestin. (I) Quantification of immunofluorescence staining of PD-1+ SOX2+ or PD-1+ nestin+ cells within the tumor microenvironment. Quantification was performed in three to four fields of view (FOVs) of each patient. Each circle is of a different patient with GBM, and the color of the dots in both panels match to the same subject. Green, 026-1; purple, 101220; orange, 110907; blue, 100819; red, 110512; black, 101029; yellow, 1085. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Data are represented as means ± SEM. See also fig. S1 and table S1.
Fig 3: Systemically administrated PD-1/PD-L1 Pb-Tx are preferentially activated in protease-rich tumor microenvironments eliciting antitumor immune responses that are comparable with responses of the unmasked antibodies. A, Growth of syngeneic MC38 tumors in C57BL/6 mice was monitored in response to the anti–PD-L1 muC5H9v2 or the PD-L1–targeted Pb-Tx CX-630. Mice bearing MC38 tumors of ~80 mm3 were treated by intraperitoneal injection starting day 0 with 5 mg/kg, twice weekly for 3 weeks; n = 10/group. Data shown are representative of 4 independent experiments. *, P = 0.05 for each versus isotype, one-way analysis of variance with Dunnett test. B, Female C57BL/6 mice with established MC38 tumors, average volume 45 to 80 mm3, were randomized into groups of 10 mice and administered anti–PD-1 (J43v2), PD-1–targeted Pb-Tx (CX-284), or control mIgG2a by intraperitoneal injection twice weekly at 10 mg/kg for a total of 6 injections. Tumor volumes were monitored and are shown as a function of time. Data shown are representative of 4 independent experiments. *, P = 0.05 for each versus isotype, one-way analysis of variance with Dunnett test. C, Tumor-bearing mice were treated with a combination of anti–CTLA-4 (10 mg/kg, twice weekly for 3 weeks) and JV43v2 or CX-284 (10 mg/kg, twice weekly for 3 weeks) and monitored for tumor growth. Data shown are representative of 3 independent experiments. *, P = 0.05 for each versus CTLA-4 mAb group, one-way analysis of variance with Dunnett test. D, Mice bearing MC38 tumors (~40 mm3) in the right flank were treated with CX-284 (10 mg/kg, twice weekly for 3 weeks; n = 35). Of that cohort, mice that had undergone complete tumor regression because of CX-284 treatment were rechallenged with a subcutaneous injection of MC38 cells in the left flank and monitored for tumor growth without additional therapy alongside a naïve control group. Data shown are pooled from 3 independent experiments. E, C57BL/6 mice bearing MC38 tumors roughly ~80 mm3 in size were treated with 5 mg/kg of muC5H9v2, CX-630, or isotype control on days 0, 4, and 7. On day 8, the tumors were excised, fixed with formalin, and embedded in paraffin. Microphotographs of tumor-tissue sections stained with an anti-CD8 antibody are shown at 10× magnification. F, Tumor and normal tissues were harvested from MC38 tumor–bearing mice 4 days after treatment with a single dose of CX-630 (5 mg/kg). Concentrations of activated Pb-Tx were determined by Western capillary electrophoresis using an anti-idiotype antibody. Data shown are representative of 3 independent experiments.
Fig 4: PD-1 on BTICs promotes intracranial tumor growth in mice.(A) Schematic diagram depicts implantation of Pdcd1-knockdown or OE cells into the striatum of mice. Kaplan-Meier analysis to assess the survival of wild-type mice i4mplanted with (B) Pdcd1 knockdown or (C) overexpressing murine BT0309. Cells transduced with lentiviral vectors coding nontarget shRNA or transfected with empty PiggyBac vector were considered as controls for knockdown (shRNA control) or OE (OE control) BTICs, respectively. (D) Representative images of immunofluorescence staining of PD-1, SOX2, and p65 in sections collected from C57BL/6 wild-type mice implanted with Pdcd1-knockdown or shRNA controls. Nuclear translocation (yellow arrowheads) and cytoplasmic localization (blue arrowheads) of p65 in BTICs are shown on the images. (E) Kaplan-Meier analysis of Rag1 KO mice implanted with Pdcd1-knockdown or shRNA controls of mBT0309. Representative T2-weighted MRI images (F) at day 50 of Rag1 KO mice implanted with Pdcd1-knockdown or (G) at day 54 of Rag1 KO mice implanted with Pdcd1 OE mBT0309 (tumor demarcated with red outlines). Quantitation of tumor volume from MRI images of mice implanted with (H) Pdcd1 knockdown or (I) OE BTICs versus respective vector controls. Results are representative of n = 2 to 3 independent experiments. Unpaired (two-tailed) t test was used to assess significance between two groups in (I). For more than two groups in (H), one-way ANOVA with Tukey’s post hoc was used. Kaplan-Meier survival curves were analyzed for statistical differences between groups using the log-rank Mantel-Cox test: ***P < 0.001 and ****P < 0.0001 compared to respective vector control. Data are represented as means ± SEM.
Fig 5: PD-L1–targeting Pb-Tx exhibits protease-dependent blocking activity in vitro. A, Serial dilutions of muC5H9v2 mAb or Pb-Tx CX-630, either pretreated or not with recombinant human protease (uPA), were incubated with immobilized PD-L1-Fc. The binding affinity of the agents was measured using an anti-mouse HRP-conjugated secondary antibody and is shown in relation to the concentration. Data shown are representative of 3 independent experiments. B, The capacity of CX-630 to block ligand binding was impaired relative to the parental unmasked antibody, as indicated by a competition ELISA assay. Dilutions of muC5H9v2 mAb or CX-630, either pretreated or not with iPA, were mixed with biotinylated PD-1 in a well that was precoated with PD-L1-Fc. The amount of PD-1 bound to PD-L1 was measured using a streptavidin–HRP conjugate and is shown in relation to the amount of blocking antibody or Pb-Tx. Data shown are representative of 3 independent experiments. C, CMV-positive human PBMCs were plated at 250,000 cells/well and stimulated with 5 µg/mL CMV lysate in the presence of CX-072 Pb-Tx, C5H9v2 mAb, or isotype control for 4 days, at which point IFN? was measured in the supernatants by ELISA. Data shown are representative response from one donor (n = 3 donors tested) of 3 independent experiments. All data points represent the mean ± SD. Abs, absorbance.
Supplier Page from OriGene Technologies for PD1 (PDCD1) (NM_005018) Human Untagged Clone